October 6, 2009Catheterization and Cardiovascular Interventions
Transcatheter aortic valve implantation for high risk patients With severe aortic stenosis using the Edwards Sapien balloon‐expandable bioprosthesis: A single centre study with immediate and medium‐term outcomes
Why the study?
Does transcatheter aortic valve implantation improve hemodynamics and clinical outcomes in high-risk patients with severe aortic stenosis?
Population
46 high-risk patients with symptomatic severe aortic stenosis, mean AVA 0.63 +/- 0.2 cm2, mean gradient 54…
Design
Cohort
Follow-up
mean 7.4 +/- 4.4 months and 8.3 +/- 5.0 months
Authors
Discussion
Loading...
Member takes
Implication
Supports TAVI feasibility with hemodynamic/symptom gains in high-risk severe AS; leaves open randomized confirmation of durability and comparisons.
Structured PICO
Does transcatheter aortic valve implantation improve hemodynamics and clinical outcomes in high-risk patients with severe aortic stenosis?
P
Population
46 high-risk patients with symptomatic severe aortic stenosis (estimated operative mortality risk >15%), mean AVA 0.63 +/- 0.2 cm2, mean gradient 54 +/- 16 mm Hg. Predicted operative mortality 25.3% by logistic Euroscore and 8.7% by STS score.
I
Intervention
Transcatheter aortic valve implantation (TCAVI) with 23 mm or 26 mm Edwards Sapien bioprosthesis via transapical (n=30) or transfemoral (n=16) approach.
O
Outcome
Procedural success, 30-day mortality, and medium-term changes in aortic valve area, transaortic mean gradient, and NYHA classhard clinical
TCAVI using the Edwards Sapien bioprosthesis is feasible and provides significant hemodynamic and symptomatic improvement with acceptable 30-day mortality in high-risk patients with severe aortic stenosis.
Cite This Study
Osten et al. (2009) studied this question.